3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Other hematologic neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Glioblastoma
3
Gliosarcoma
2
Stomach Neoplasms
1
Sarcoma
1
Neuroblastoma
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
16
Filgrastim
15
Etoposide
10
Carboplatin
10
Peripheral Blood Stem Cell Transplantation
8
Melphalan
8
Magnetic Resonance Spectroscopy
7
Granulocyte Colony-Stimulating Factor
7
Busulfan
7
Thiotepa
6
Temozolomide
6
Radiotherapy
6
Ifosfamide
6
etoposide phosphate
5
X-Rays
5
Topotecan
5
Phantoms, Imaging
5
Doxorubicin
5
Cisplatin
5
Vincristine
4
Specimen Handling
4
Nuclear Medicine Department, Hospital
4
Mesna
4
selpercatinib
3
sargramostim
3
pembrolizumab
3
palbociclib
3
aldesleukin
3
Sirolimus
3
Radiosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
capmatinib
×
CNS
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled